用户名:  密码:   
网站首页即时通讯活动公告最新消息科技前沿学人动向两岸三地人在海外历届活动关于我们联系我们申请加入
栏目导航 — 美国华裔教授专家网科技动向生物医学
关键字  范围   
 
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
2020/8/8 18:53:49 | 浏览:264 | 评论:0
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
 
     
TOP STORIES
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
 
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
 
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
BIOPROCESSING
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
CANCER & DISEASE RESEARCH Sponsored by Beckman Coulter
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
CELL BIOLOGY
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
DRUG DISCOVERY & DEVELOPMENT
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
GENOMICS Sponsored by Nvidia
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
IMMUNOLOGY Sponsored by Beckman Coulter
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
PROTEOMICS
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapiesInsights
Exclusive content for Science Advisory Board members on trends and outcomes that are influencing the future of scientific research.
 
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapiesCommunities
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
 
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapiesRewards
Earn points for contributing to research. Redeem your points for merchandise, travel, or even to help your favorite charity.
 
 

 

Dear Science Advisory Board Member,

As more molecular coronavirus research becomes published, we are getting a better view of the SARS-CoV-2 virus and its pathogenicity. Particularly, how the virus leverages nonstructural proteins to undermine host immune defenses and how blocking these proteins may effectively stop the virus in its tracks. More detailed molecu lar views of these accessory proteins will guide structure-based drug design and bring us one step closer to beating this pandemic.

As an example, researchers from the U.S. National Institutes of Health(NIH)and other academic institutions in the U.S. described how they rapidly developed a SARS-CoV-2 vaccine candidate based on the genetic sequences of the virus and previous work with messenger RNA(mRNA)vaccine delivery systems.

This vaccine candidate, mRNA-1273, is being jointly developed by the NIH and Moderna and is part of the agency's large-scale clinical trial protocol, Accelerating COVID-19 Therapeutic Interventions and Vaccines(ACTIV). The program includes both vaccines and treatments, and the NIH announced that it has launched phase II studies for the investigational monoclonal antibody Ly-CoV555 developed by Eli Lilly and AbCellera.

Other contenders, like Johnson & Johnson's Ad-26 and Inovio's Ino-4800, are posting positive preclinical results and their developers expect to begin late-stage clinical testing soon. Funding through the U.S. government's Operation Warp Speed program is still being allocated to new vaccine candidates, such as a recombinant protein-based vaccine being developed by Sanofi and GlaxoSmithKline.

Aside from COVID-19 developments, several notable advances in immunotherapies and gene therapies were announced this week. Bio-Rad won an important patent infringement appeal over 10X Genomics, which gives it an edge in the gene expression products market. Meanwhile, Omega Therapeutics is advancing its epigenomic programming platform in clinical trials, and SAB Therapeutics has begun testing a seasonal flu immunotherapy.

Stay healthy and safe.

SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
Samantha Black, PhD
The Science Advisory Board Editor
editor@scienceboard.net
相关栏目:『生物医学
《英国血液学杂志》:COVID-19促使免疫系统释放T细胞消灭癌症 2021-04-17 [67]
德国科学家借助人工智能识别出一百六十五个新癌症基因 2021-04-17 [42]
英、美国际联合专家团队新研究:全面描述肿瘤内异质性 2021-04-17 [21]
mRNA 技术会改变世界吗? 2021-04-14 [663]
布朗大學「腦門」團隊:「意念控制」真的要走入現實 2021-04-11 [74]
伍斯特大学研究警告:低脂肪素食饮食,让男性睾酮水平下降26% 2021-04-10 [127]
美国范德堡大学新发现颠覆过去百年来的癌症新陈代谢模型 2021-04-10 [106]
哈佛大学干细胞研究阐明压力如何影响毛发生长 2021-04-10 [71]
美国国家标准与技术研究院:人造细胞可像天然的那样生长分裂 2021-04-10 [72]
利兹大学:食用香肠、火腿 导致患痴呆症甚尔茨海默病的风险增加 2021-04-10 [102]
相关栏目更多文章
最新图文:
游天龙:《唐人街》是如何炼成的:UCLA社会学教授周敏的学术之路 :“为什么海外华人那么爱国,但是让他回国却不愿意?...“ :学术出版巨头Elsevier 彻查433名审稿人“强迫引用”黑幕 :中国336个国家重点实验室布局 :中澳政府联合出手打击洗钱和逃税漏税 大量中国居民海外账户遭冻结 :摄影师苏唐诗与寂寞百年的故宫对话6年,3万张照片美伦美奂 :大数据分析图解:2019中国企业500强 张梦然:英国惠康桑格研究所:人体内的微生物与出生方式有关
更多最新图文
更多《即时通讯》>>
 
打印本文章
 
您的名字:
电子邮件:
留言内容:
注意: 留言内容不要超过4000字,否则会被截断。
未 审 核:  是
  
关于我们联系我们申请加入后台管理设为主页加入收藏
美国华裔教授专家网版权所有,谢绝拷贝。如欲选登或发表,请与美国华裔教授专家网联系。
Copyright © 2021 ScholarsUpdate.com. All Rights Reserved.